Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Hua Medicine ( (HK:2552) ).
Hua Medicine announced a significant increase in sales revenue for 2024, attributed to the inclusion of HuaTangNing in the National Reimbursement Drug List in China. The company has taken over full commercialization responsibilities from Bayer, leading to a substantial increase in sales volume. Hua Medicine is also advancing its international expansion plans, with successful trials of its glucokinase activator in the United States and plans to submit registration applications in Macau and Hong Kong. The company is recognized for its pharmacovigilance efforts and continues to invest in manufacturing capacity to meet future market demands.
More about Hua Medicine
Hua Medicine is a pharmaceutical company focused on the development and commercialization of innovative therapies for diabetes. Their primary product, HuaTangNing, is a glucokinase activator aimed at improving glucose homeostasis in diabetic patients. The company is expanding its market presence in mainland China and preparing for international expansion, particularly in the United States.
Technical Sentiment Signal: Buy
Current Market Cap: $304.5M
Find detailed analytics on 2552 stock on TipRanks’ Stock Analysis page.